


PROGRAM 17-20 MAY 2021
ishheid

In the era of Coronaviruses

100% VIRTUAL
CONGRESS



www.ishheid.com

Co-Chairs

Alain LAFEUILLADE, France
Christina PSOMAS, France
Jean-Pierre ROUTY, Canada
Hervé TISSOT-DUPONT, France

Steering Committee

Patricia ENEL, France
Patrick MALLON, Ireland
Chloe ORKIN, England
Patrick PHILIBERT, France
Jean-Marc POLESEL, France
Vicente SORIANO, Spain
Stefano VELLA, Italy

Scientific Committee

José Ignacio BERNARDINO, Spain
Thomas BOURLET, France
Adrian CURRAN, Spain
Jean-François DELFRAISSY, France
Magnus GISSLEN, Sweden
Marie-Lise GOUGEON, France
Philippe HALFON, France
Sabine KINLOCH, England
Santiago MORENO, Spain
Mark NELSON, England
Jean-Jacques PARIENTI, France
Guido POLI, Italy
Valérie POURCHER, France
Lene RYOM, Denmark
Caroline SABIN, England
Sergio SERRANO, Spain
Caroline SOLAS, France
Bruno SPIRE, France
Ferdinand WIT, The Netherlands

Organization

OVERCOME
13-15 rue des Sablons
75116 Paris, France
Ph.: +33 (0)1 40 88 97 97
Email: isheid@overcome.fr

Dear Friends, dear Colleagues,

We are pleased to welcome you to the International Symposium on HIV and emerging Infectious Diseases (ISHEID) e-platform for 4 days, from May 17 to May 20, 2021. This year edition exceptionally takes place online because of the Covid-19 pandemic.

The understanding of HIV and HCV infections continues to grow rapidly, especially regarding our ability to develop novel prevention and therapeutic strategies that will lead to the reduction of new infections. The burden of non-communicable diseases in HIV infected subjects implicates a multidisciplinary approach of the infection and the need of close interactions with specialists from other disciplines.

ISHEID 2021 will dedicate a privileged place to state-of-the art presentations, as well as to debates among experienced and younger investigators regarding new data and their implications.

This event will have invited lectures by European and International leaders, as well as oral abstracts and poster presentations.

It will be unique in its approach, as it will engage basic scientists and clinicians from the HIV, HCV and emerging infectious diseases fields.

Have a pleasant Congress!

Alain LAFEUILLADE, Christina PSOMAS,

Jean-Pierre ROUTY & Hervé TISSOT-DUPONT

on behalf of the steering committee

PROGRAM AT A GLANCE *(Central European Summer Time = CEST)*

MONDAY, MAY 17, 2021	TUESDAY, MAY 18, 2021	WEDNESDAY, MAY 19, 2021	THURSDAY, MAY 20, 2021
17.00 Opening ceremony			
17.15 - Break	17.00 Vaccines	17.00 How to end the HIV pandemic?	17.00 Climate and social political changes, HIV and epidemics
17.30 Lessons from Covid-19: pitfalls and promise	18.00 - Break		
18.30 - Break	18.15 Industry-sponsored symposium	18.15 Industry-sponsored symposium	18.15 Industry-sponsored symposium
18.45 ART: questions in the era of bitherapies	19.15 - Break		
19.45 - Break	19.30 Comorbidities and microbiote	19.30 SARS-CoV-2	19.30 Sexually transmitted infections
20.00 Oral communication & discussed posters on pandemic and emergent viruses			20.30 - Break
			20.35 Closing ceremony

CEST 17.00
17.15

OPENING CEREMONY

Alain LAFEUILLADE, La Valette-du-Var, France
Christina PSOMAS, European Hospital, Marseille, France
Jean-Pierre ROUTY, McGill University Health Centre, Montreal, Canada

17.15 – 17.30 Break

CEST 17.30
18.30

LESSONS FROM COVID-19: PITFALLS AND PROMISE



In partnership with the EACS Young Investigators

Chairs: *Christina PSOMAS, European Hospital, Marseille, France*
Annemarie WENSING, University Medical Center, Utrecht, Netherlands

Moderator: *Tristan BARBER, Royal Free London NHS Foundation Trust, London, England*

- **HIV and COVID-19**
Christoph SPINNER, University Hospital Klinikum rechts der Isar, Munich, Germany
- **Research pitfalls; what has COVID taught us**
Laura WATERS, Mortimer Market Center, Central and North West London NHS Foundation Trust, London, England

18.30 – 18.45 Break

CEST 18.45
19.45

ART: QUESTIONS IN THE ERA OF BITHERAPIES

Chairs: *Sabine KINLOCH, Institute of Immunity & Transplantation, London, England*
Jean-Pierre ROUTY, McGill University Health Centre, Montreal, Canada

- **Targeting latent HIV to induce immune-mediated clearance of infected cells**
Jeff MURRY, Foster City, USA
- **Dual therapy against trithérapies: inflammation Vs toxicity**
Casper ROKX, Erasmus Medical Center, Rotterdam, the Netherlands
Christina PSOMAS, European Hospital, Marseille, France

19.45 – 20.00 Break

CEST 20.00
21.00

ORAL COMMUNICATIONS & DISCUSSED POSTERS ON PANDEMIC AND EMERGENT VIRUSES

Chairs: *Guido POLI, Vita-Salute San Raffaele University, Milano, Italy*
Santiago MORENO, Hospital Ramón y Cajal, Madrid, Spain

O1. Impact of early antiretroviral therapy on tissue resident myeloid cells in the liver and lung of SIV-infected rhesus macaques

Authors: J. CLAIN, H. RABEZANAHARY, G. RACINE, G. BENMADID-LAKTOU, O. ZGHIDI-ABOUZID, J. ESTAQUIER
Quebec University Hospital, Laval University, Research Center, Quebec - Canada

O2. Sexual satisfaction in women living with HIV. Are they the forgotten ones?

Authors: L. GONZÁLEZ RODRIGUEZ¹, J. BALIÑAS², R. SCHULTZE³, L. LABAJO³, M.D.G. MUÑOZ³, Á. MENA²

¹*Obstetrics And Gynecology Service, Álvaro Cunqueiro University Hospital, Vigo - Spain*

²*Infectious Pathology Unit, A Coruña University Complex, A Coruña - Spain*

³*Infectious Pathology Unit, Álvaro Cunqueiro University Hospital, Vigo - Spain*

O3. Influence of Hepatitis E virus genetic variability on the viral circulation between humans and environment

Authors: E. SCHVOERER¹, C. HARTARD¹, H. FENAUX¹, A. DE ROUGEMONT², E. LAUGEL¹, S. BERGER¹, J.P. BRONOWICKI³, I. BERTRAND⁴

¹*Nancy University Hospital, Laboratory of Virology, Vandœuvre-Lès-Nancy - France*

²*Dijon University Hospital, Laboratory of Virology, Dijon - France*

³*Nancy University Hospital, Hepato-Gastroenterology, Vandoeuvre Les Nancy - France*

⁴*Lcpme (laboratoire De Chimie Physique Et Microbiologie Pour Les Matériaux Et L'environnement), Umr 7564 Cnrs-Ui, Campus Santé Brabois, Vandoeuvre Les Nancy - France*

O4. Effect of Metformin in non-diabetic people living with HIV: weight loss, decrease in inflammation and modification of the gut microbiota

Authors: S. ISNARD¹, J. LIN¹, T. VARIN², A. MARETTE², D. PLANAS³, C. VAN DER LEY⁴, P. ANCUTA³, J.P. ROUTY¹

¹*Mcgill University Health Centre, Montreal - Canada*

²*Laval University, Québec - Canada*

³*Montreal University, Montreal - Canada*

⁴*University Of Groningen, Groningen - Netherlands*

O5. Extensive proteomic and transcriptomic changes quench the TCR/CD3 activation signal in latently HIV-1 infected T cells

Authors: E. CARLIN, B. GREER, A. DUVERGER, F. WAGNER, D. MOYLAN, A. DALECKI, S. SABBAJ, O. KUTSCH
UAB, Birmingham - United States

DP1. Tracing the patterns of HIV-1 transmission among individuals with different diagnosis status in Greece

Authors: E-G. KOSTAKI¹, S. LIMNAIOS¹, S. PATRINOS², D. CHATZIDIMITRIOU³, G. MAGIORKINIS¹, L. SKOURA³, V. SYPSA¹, A. HATZAKIS¹, D. PARASKEVIS¹

¹*Department Of Hygiene, Epidemiology And Medical Statistics, Medical School, National And Kapodistrian University Of Athens, Athens - Greece*

²*Hellenic Center For Diseases Control And Prevention, Marousi - Greece*

³*National Aids Reference Center Of Northern Greece, Department Of Microbiology, Aristotle University Medical School, Thessaloniki - Greece*

DP2. Identification of fast-growing HIV-1 transmission clusters in Spain and its potential application in Public Health

Authors: H. GIL, E. DELGADO, S. BENITO, M. SÁNCHEZ, J. CAÑADA, E. GARCÍA-BODAS, M.M. THOMSON,
 Spanish group for the study of new HIV diagnoses

National Microbiology Centre. Carlos III Health Institute, Majadahonda - Spain

DP3. No impact of SARS-CoV-2 on the Activation Status of ART+HIV+ Patients

Authors: M. NIKOLOVA¹, R. EMILOVA¹, Y. TODOROVA¹, N. YANCHEVA², I.ALEXIEV³, R. GROZDEVA², D. STRASHIMIROV², N. KUYCHUKOVA²

¹*Nrl Of Immunology, National Centre Of Infectious And Parasitic Diseases, Sofia - Bulgaria*

²*Specialized Hospital for Active Treatment of Infectious and Parasitic Diseases, Sofia - Bulgaria*

³*Nrl Of HIV, National Center of Infectious and Parasitic Diseases, Sofia - Bulgaria*

DP4. Factors associated with willingness to participate in end-of-life cure research: perspectives from People Living with HIV

Authors: D. LESSARD¹, M. BILODEAU², P. KEELER³, J.P. ROUTY⁴, E.A. COHEN⁵, K. DUBÉ⁶, B. LÉBOUCHÉ¹, C. COSTINIUK⁴

¹Canadian Institutes Of Health Research Strategy For Patient-Oriented Research Mentorship Chair In Innovative Clinical Trials, Montreal - Canada

²Ontario Aids Network, Toronto - Canada

³Aids Community Care Montreal, Montreal - Canada

⁴Research Institute of the Mcgill University Health Centre, Montreal - Canada

⁵Montreal Institute of Clinical Research, Department of Microbiology, Infectiology and Immunology, Montreal University, Montreal - Canada

⁶Public Health Leadership Program, University Of North Carolina At Chapel Hill And Chapel Hill And Gilings School Of Global Public Health, Chapel Hill - USA

DP5. Fibrosis regression in HIV-HCV coinfectd patients treated by DAAs

Authors: G. LAURICHESSE¹, P. JAFFEUX², A. MIRAND³, N. MROZEK¹, M. VIDAL¹, V. CORBIN¹, H. LAURICHESSE¹, C. JACOMET¹

¹Clermont-Ferrand University Hospital, Infectious Diseases, Clermont-Ferrand - France

²Clermont-Ferrand University Hospital, Statistics, Clermont-Ferrand - France

³Clermont-Ferrand University Hospital, Virology, Clermont-Ferrand - France

DP6. Differential Serotyping of HEV genotype 1 and 3

Authors: M. SHATA¹, E. ABDEL-HAMEED¹, S. ROUSTER¹, H. HETTA², K. SHERMAN³

¹University of Cincinnati, Cincinnati - USA

²Department of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut - Egypt


³University of Cincinnati, Internal Medicine, Digestive Dis., Cincinnati - USA



CEST 17.00
18.00**VACCINES**

Chairs: Diana FINZI, National Institute of Health, Bethesda, USA
Jean-Pierre ROUTY, McGill University Health Centre, Montreal, Canada

- **Vaccines update for HIV and immunosuppressed patients**
Anna-Maria GERETTI, London, England
- **Post-infection Vs post-vaccinal SARS-CoV-2 immunity: challenges and reality**
Olivier SCHWARTZ, Pasteur Institute, Paris, France



18.00 – 18.15 Break / Pause

CEST 18.15
19.15**INDUSTRY-SPONSORED SYMPOSIUM**

More information page 10



19.15 – 19.30 Break / Pause

CEST 19.30
20.50**COMORBIDITIES AND MICROBIOTE**

Chairs: Jose Ignacio BERNARDINO, La Paz University Hospital, Madrid, Spain
Christina PSOMAS, European Hospital, Marseille, France

- **The microbiome**
Sergio SERRANO VILLAR, Hospital Ramon y Cajal, Madrid, Spain
- **NASH and obesity and weight gain in hepatitis and HIV**
Paddy MALLON, UCD School of Medicine, Dublin, Ireland
- **Role of hepatotropic viruses in the pathogenesis of cancer in PLWH**
Alvaro MENA, University Hospital, Coruna, Spain

O6. Myocardial abnormalities in HIV: Insights from Cardiac Magnetic Resonance Imaging (MRI)

Authors: G. MANMATHAN¹, L. CHACKO², R. MURKI², T. KOTECHA², C. LITTLE², T. BARBER¹, S. KINLOCH¹, M. JOHNSON¹, R. RAKHIT²

¹Royal Free Hospital, London - United Kingdom

²University College London, London - United Kingdom

O7. Cardiomyopathy, pulmonary hypertension and myocarditis not as prevalent in well controlled HIV: H-ART to Heart study

Authors: G. MANMATHAN, N. NGWU, J. JOHNSON, C. LITTLE, T. KOTECHA, M. JOHNSON, R. RAKHIT

Royal Free Hospital, London - United Kingdom

DP7. Nlrp3 inflammasome activation in peripheral blood leukocytes from HIV-infected patients and its contribution to chronic inflammation

Authors: V. NUNES CORDEIRO LEAL, E.C. DOS REIS, A. PONTILLO

University Of Sao Paulo, Sao Paulo - Brazil

CEST 17.00
18.00**HOW TO END THE HIV PANDEMIC?**

Chairs: *Caroline SABIN, Royal Free Campus, London, England*
Christina PSOMAS, European Hospital, Marseille, France

- **London experience**

Alison BROWN, Public Health England, London, England

- **Fast track cities, where are we?**

Bertrand AUDOIN, International Association of Providers of AIDS Care, Paris, France

18.00 – 18.15 Break

CEST 18.15
19.15**INDUSTRY-SPONSORED SYMPOSIUM**

More information page 10

19.15 – 19.30 Break

CEST 19.30
20.30**SARS-COV-2**

Chairs: *Valérie POURCHER, Hôpital de la Pitié-Salpêtrière, Paris, France*
Hervé TISSOT DUPONT, Aix-Marseille University, Marseille, France

- **Neurological complications of COVID-19, in acute disease and long-term**

Arvid EDÉN, University of Gothenburg, Gothenburg, Sweden

- **Genetic determinants of COVID-19 disease severity**

Manuel CORPAS, Cambridge University, Cambridge, England

DP8. Viral rebound (VR) 14 years after discontinuation of antiretroviral therapy (ART)

Authors: S. KINLOCH-DE LOES¹, L. VANDEKERCKHOVE², F. BURNS³, M. JOHNSON¹

¹Royal Free Hospital, London - United Kingdom

²University of Ghent, Ghent - Belgium


³Ucl, London - United Kingdom

DP9. Frailty phenotype is associated with antiretroviral exposure among older persons living with HIV

Authors: G. FELKER¹, P. ENEL¹, N. PETIT¹, I. RAVAUX¹, A. DARQUE¹, F. RETORNAZ²

¹Public University Hospital of Marseille, Marseille - France

²Department Of Public Health, Self-Perceived Health Assessment Research Unit Ea3279, Aix-Marseille University, Marseille - France



CEST 17.00
18.00**CLIMATE AND SOCIO-POLITICAL CHANGES, HIV AND EPIDEMICS**

Chairs: Stefano VELLA, Superior Health Institute, Rome, Italy
Ferdinand WIT, Academic Medical Center Amsterdam, Netherlands

- **HIV and global health in the era of coronavirus**
Stefano VELLA, Superior Health Institute, Rome, Italy
- **HTLV-1 has become a new STI**
Carmen DE MENDOZA, International University of La Rioja, Madrid, Spain



18.00 – 18.15 Break

CEST 18.15
19.15**INDUSTRY-SPONSORED SYMPOSIUM**

More information page 10

 Room 1 /  Room 2



19.15 – 19.30 Break

CEST 19.30
20.30**SEXUALLY TRANSMITTED INFECTIONS**

Chairs: Patricia ENEL, Aix-Marseille University, Marseille, France
Patrick PHILIBERT, European Hospital, Marseille, France

- **Impact of COVID on sexual behaviour/risks/testing**
Cath MERCER, University College London, London, England
- **New challenges in STIs: M. Genitalium, XDR N.gonorrhoeae**
Vicente SORIANO, UNIR Health Sciences School, Madrid, Spain

O8. Sexual Transmission of HTLV-1 and expanded spectrum of clinical manifestations

Authors: V. SORIANO¹, J.M. RAMOS², H. PINARGOTE², C. DE MENDOZA³, A. SPANISH
H T L V NETWORK³

¹Unir Health Sciences School & Medical Center, Madrid - Spain

²General University Hospital & Miguel Hernandez University, Alicante - Spain

³Puerta De Hierro University Hospital & San Pablo University-Ceu, Madrid - Spain

DP10. HIV-2 in Spain - steadily increasing and new challenges

Authors: V. SORIANO¹, T. CABEZAS², E. CABALLERO³, A.B. LOZANO², C. DE MENDOZA⁴

¹Unir Health Sciences School & Medical Center, Madrid - Spain

²Hospital De Poniente, Almeria - Spain

³Hospital Vall D'hebron, Barcelona - Spain

⁴Puerta De Hierro Research Institute, Madrid - Spain

CEST 20.35

CLOSING CEREMONY

Alain LAFEUILLADE, La Valette-du-Var, France

Christina PSOMAS, European Hospital, Marseille, France

TUESDAY, MAY 18, 2021

CEST 18.15
19.15

INDUSTRY-SPONSORED SYMPOSIUM

**QUALITY OF LIFE MATTERS! TAILOR CARE TO OPTIMIZE IT IN PLWH****Chair:** *Jonathan SCHAPIRO, National Hemophilia Center, Tel Aviv, Israel*

- **Future of NNRTIs: state of the ART of NNRTI Resistance**
Jonathan SCHAPIRO, National Hemophilia Center, Tel Aviv, Israel
- **Tailoring Care for the Body**
Paddy MALLON, UCD School of Medicine, Dublin, Ireland
- **Tailoring Care for Women with HIV.**
Relevant potential DDIs in women
What about aging women?
Karine LACOMBE, Saint Antoine Hospital, Paris, France

WEDNESDAY, MAY 19, 2021

CEST 18.15
19.15

INDUSTRY-SPONSORED SYMPOSIUM

**BEYOND VIRAL SUPPRESSION, WHAT ARE THE CHALLENGES IN THE MANAGEMENT OF HIV INFECTION IN 2021?****Chair:** *Christina PSOMAS, European Hospital, Marseille, France*

- **Inflammation and immune markers**
Christina PSOMAS, European Hospital, Marseille, France
- **Sleep disorders and depression**
Anne MOROY, Hôtel Dieu Hospital, Paris, France
- **Prevention and management of drug interactions**
Olivier ROBINEAU, Gustave Dron Hospital, Tourcoing, France

THURSDAY, MAY 20, 2021

CEST 18.15
19.15INDUSTRY-SPONSORED SYMPOSIUM
SYMPOSIUM PARRAINÉ PAR L'INDUSTRIE**LONG-TERM VIROLOGICAL AND CLINICAL IMPACT OF DUAL THERAPY**
L'IMPACT VIROLOGIQUE ET CLINIQUE A LONG TERME DE LA BITHÉRAPIE**Chair:** *Christine KATLAMA, Pitié Salpêtrière Hospital, Paris, France*

- **Dual therapies: what are the impacts on HIV reservoirs?**
Les bithérapies : quels sont les impacts sur les réservoirs du VIH ?
Véronique AVETTAND-FENOEL, Necker-Enfants Malades University Hospital, Paris, France
- **What is the impact of long term dual therapy on bone, renal inflammation and metabolics?**
Quel est l'impact de la bithérapie à long terme sur les os, l'inflammation rénale et le métabolisme ?
Laura WATERS, Mortimer Market Center, CNWL, London, England

Quality of life matters! Tailor care to optimize it in PLWH

Virtual symposium

Moderator

Jonathan Schapiro

Director, HIV/AIDS
National Hemophilia Center
Sheba Medical Center
Ramat Gan, Israel

Faculty

Karine Lacombe

Head
Department of Infectious
Diseases and Tropical Medicine
Saint-Antoine Hospital
Sorbonne Université
Paris, France

Paddy Mallon

Professor of Microbial
Diseases, Director UCD Centre
for Experimental Pathogen
Host Research (CEPHR), St.
Vincent's University Hospital
Dublin, Ireland

Tuesday, 18 May 2021

18:15 – 19:15 (CET)

12:15 – 13:15 (EST)

Moderator: Jonathan Schapiro (Israel)

Agenda

18:15 – 18:20	Welcome and introduction <i>Jonathan Schapiro</i>
18:20 – 18:35	Future of NNRTIs: State of the ART of NNRTI resistance <i>Jonathan Schapiro</i>
18:35 – 18:50	Tailoring care for the body <i>Paddy Mallon</i>
18:50 – 19:05	Tailoring care for women with HIV <i>Karine Lacombe</i>
19:05 – 19:15	Q&A <i>All</i>

Agenda may be subject to change pending speaker confirmation

01. Basic and translational science**P1. Deciphering the link between HIV seropositivity and religious minority in India**

Authors: A. Siddhanta, A.K. Singh
Ipe Global - New Delhi (India)

P2. Association between HIV transmission patterns and k-cores of social networks among people who inject drugs in Greece

Authors: G. Nikolopoulos ¹, E.G. Kostaki ², K. Pantavou ¹, A. Hadjiikou ¹, K. Voskarides ¹, E. Christaki ¹, S. Friedman ³, D. Paraskevis ²
¹*Medical School, University Of Cyprus - Nicosia (Cyprus)*
²*Department Of Hygiene, Epidemiology And Medical Statistics, Medical School, National And Kapodistrian University Of Athens - Athens (Greece)*
³*Department Of Population Health, Nyu Grossman School Of Medicine - New York City (United States)*

P3. Atypical serology in an HIV-infected patient treated at Fiebig stage 1: evaluation of different diagnostic kits

Authors: E. Jeanmaire ¹, C. Hartard ², C. Prin Mathieu ³, V. Venard ², E. Schvoerer ², H. Jeulin ²
¹*Service De Maladies Infectieuses Et Tropicales, Chru De Nancy Brabois - Vandœuvre-Lès-Nancy (France)*
²*Laboratoire De Virologie, Service De Microbiologie, Chru De Nancy Brabois Vandœuvre-Lès-Nancy (France)*
³*Plateau Technique Automatisé, Pôle Des Laboratoires, Chru De Nancy Brabois Vandœuvre-Lès-Nancy (France)*

P4. Immunological characterization of non-responders to Direct Acting Antiviral Therapy in Egyptian Patients with Chronic Hepatitis C

Authors: M. Shata ¹, H. Hetta ², M. El-Mokhtar ², M. Mekky ³, H. Sayed ⁴, M. Haridy ⁴, M. Khalaf ⁴, A. Zahran ⁵
¹*University Of Cincinnati, Internal Medicine, Digestive Dis. - Cincinnati (United States)*
²*Assiut University, Faculty Of Medicine, Microbiology And Immunology Dept. - Assiut (Egypt)*
³*Assiut University, Faculty Of Medicine, Dept Of Tropical Medicine And Gastroenterology Assiut (Egypt)*
⁴*Ministry Of Health, Center For Management Of Viral Hepatitis - Assiut (Egypt)*
⁵*South Egypt Cancer Institute, Dept Of Clinical Pathology - Assiut (Egypt)*

P5. Characterization of HIV epidemics in general population in Kyrgyzstan

Authors: M. Sivay ¹, A. Totmenin ¹, V. Ivlev ¹, I. Osipova ¹, T. Nalimova ¹, E. Narmatova ², U. Chokmorova ³, A. Bekbolotov ³, N. Gashnikova ¹
¹*State Research Center Of Virology And Biotechnology "vector" - Koltsovo (Russian Federation)*
²*Osh Regional Center Of Aids Prevention And Treatment - Osh (Kyrgyzstan)*
³*Republican Aids Center - Bishkek (Kyrgyzstan)*

P6. Propagation of an HIV-1 CRF72_BF-like cluster of Brazilian ancestry in Spain

Authors: M. Thomson, J. Cañada, H. Gil, M. Sánchez, S. Benito, E. García-Bodas, E. Delgado, S. Group For The Study Of New Hiv Diagnoses
Centro Nacional De Microbiología, Instituto De Salud Carlos Iii - Majadahonda (Madrid) (Spain)

P7. Vulnerabilities and HIV: a co-constructed health pathway between the concerned people and healthcare stakeholders

Authors: J. Robert, M. Mailland
Réseau Santé Marseille Sud - Marseille (France)

P8. Health-related Quality of Life among Adults Living with HIV: A Cross-Sectional

Survey in Armenia

Author: T. Balayan

*National Center For Disease Control And Prevention - Yerevan (Armenia)***P9. Emerging pathogen and changing sensitivity pattern of pyogenic meningitis in a teaching institute from India**

Author: D. Kasana

*Professor And Consultant - Delhi (India)***02. Clinical research**

P1. Impact of IL-10 (C-592A) polymorphism on cytokine plasma levels in HIV-infected UkrainiansAuthors: A. Piddubna ¹, M. Chemych ²¹*Central Clinical Hospital Sumy - Sumy (Ukraine)*²*Sumy State University - Sumy (Ukraine)***03. HIV, hepatitis and ageing comorbidities**

P1. Late Presenters Among Newly Diagnosed Individuals with HIV/TB co-infectionAuthors: M. Nosik ¹, N. Chistyakova ², A. Sobkin ²¹*I.i. Mechnikov Institute Of Vaccines And Sera - Moscow (Russian Federation)*²*G.a. Zaharyan Moscow Tuberculosis Clinic - Moscow (Russian Federation)***04. Clinical management of PLHIV**

P1. Prevalence of renal disorders in people living with HIV/AIDS on ARVs treatment at the fouban district hospital, CameroonAuthors: C. Tchেমembe ¹, E. Tambo ²¹*Insam - Yaoundé (Cameroon)*²*Université Des Montagnes - Bangangté (Cameroon)***P2. Examining the efficacy in clinical practice of the dual antiretroviral therapy regimen of boosted protease inhibitors with maraviroc**

Authors: A. Katiyar, F. Burns, L. Swaden, M. Youle, T. Barber

*Royal Free Nhs Foundation Trust - London (United Kingdom)***05. Prevention**

P1. Effective Communication for Disease Prevention in Remote Areas of Sub-Saharan Africa (Community Tablet Pilot Project)Authors: I. De Brito ¹, D. Amade ²¹*Community Tablet Southern Africa - Sintra (Portugal)*²*Community Tablet Southern Africa - Maputo (Mozambique)***P2. No more no less. My health is priceless. An intervention based on Human Rights and gender equality, to promote access for sex workers to sexual health services and prevention of HIV an**

Authors: J. Ramírez Urbina, E. Ramírez Balderas

Colectivo Seres, A.c. - Fraccionamiento Arboledas (Mexico)

06. Emerging infectious diseases

P1. Bidirectional transmission of viral pathogen

Authors: J. Nandi ¹, S.S. Rathore ², B.R.J. Mathur ³

¹National Inst. Of Virology (past) - Pune (India)

²Rajasthan Zoo, - Jodhpur (India), ³Govt. Veterinary Dept. - Jodhpur (India)

P2. A novel antiviral micro-RNA targeting the NS1 protein of the H1N1 pandemic human Influenza virus and a corresponding viral escape mutation

Authors: G. Maga ¹, L. Bavagnoli ¹, G. Campanini ², E. Percivalle ², F. Baldanti ²

¹Igm-Cnr - Pavia (Italy)

²Irccs Fondazione Policlinico San Matteo - Pavia (Italy)

07. Coronaviruses

P1. Calpeptin blocks SARS-CoV-2 entry

Author: S. Mediouni

Department Of Immunology And Microbiology, The Scripps Research Institute - Jupiter (United States)

P2. Evaluating Awareness of Preventive Measures for COVID-19 and Their Presence in Behaviour of HIV-Infected Individuals during Epidemic

Authors: U. Kuimova, V. Belyaeva, N. Kozyrina, M. Goliusova

Central Scientific Research Institute Of Epidemiology Of The Russian Federal Service For Surveillance On Consumer Rights Protection And Human Wellbeing (rospotrebnadzor) Moscow (Russian Federation)


P3. In-depth longitudinal comparison of clinical specimens to detect SARS-CoV-2

Authors: G. Darcis ¹, J. Defêche ¹, A. Tytgat ², F. Bureau ², G. Laurent ², M.P. Hayette ¹,

S. Rahmouni ², Y. Belhadj ¹, M. Moutschen ¹

¹Liège University Hospital - Liège (Belgium)

²University Of Liège - Liège (Belgium)



GENERAL INFORMATION

LOGISTICS & REGISTRATIONS

OVERCOME : 13-15 rue des Sablons, 75116 PARIS, France
Tel : +33 (0)1 40 88 97 97
Email : isheid@overcome.fr

E-CONGRESS PLATFORM

You will receive the link towards the e-Congress platform a few days before the Congress.

REGISTRATIONS

Physicians	245€
Residents*/Students*	75€
AIDS association members*	75€
Paramedics*	65€

* A certificate or a supporting evidence is required / *Joindre une attestation ou un justificatif*


ONLINE REGISTRATION

Directly via the congress website:
www.isheid.com, secured payment system.

REGISTRATION DETAILS

Registration fees include
Access to the whole platform (sessions, exhibition, congress documents, ...)

Cancellation policy
Cancellation should be sent in writing to Overcome. For all cancellations received by April 17, 2021, a 60 € fee will be charged. Beyond this date, no refund will be possible.





Inégalités en santé et VIH

**DU MERCREDI 29 SEPTEMBRE APRÈS MIDI
AU VENDREDI 1^{ER} OCTOBRE MIDI 2021**

alp=xpo

2 Avenue d'Innsbruck,
38100 Grenoble

22^{ÈME} CONGRÈS

PRÉSENTIEL + VIRTUEL

DE LA SFLS - GRENOBLE

CONTACT SCIENTIFIQUE

Olivier Epaulard
Sylvie Vanderschilt

SECRETARIAT SFLS

sfls@wanadoo.fr
www.sfls.aei.fr

CONTACT ORGANISATION LOGISTIQUE

Vista - 24, rue Erlanger - 75016 Paris, France
Aude MERTON
Mail : amerton@groupevista.com
Tel : +33 (0)1 46 43 33 79

DÉVELOPPEMENT PROFESSIONNEL CONTINU

FORMAVIH
N° 72 33 09421 33
contact@formavih.org



SAVE THE DATE!

11-13 MAY 2022
isheid

Ending the viral pandemics
around the world



AVIGNON
FRANCE



www.isheid.com